A02西藥製劑(新藥開發)

Surv BioPharma成立於2022年8月，是一家由鹿兒島大學認證的生物技術新創公司，以鹿兒島大學的小戝教授所發明的技術，創造出創新藥物，以應對尚未被滿足的醫療需求。

(A) Cancer treatment with oncolytic virus immunotherapy： Surv BioPharma is promoting research and development of oncolytic virus immunotherapy for Cancer treatment collaborated with Kagoshima University. We are developing “Surv.m-CRA-1” as therapeutic medicine for malignant bone tumor and second-generation candidate with immunostimulant, “Surv.m-CRA-2-G” and ”Surv.m-CRA-2-IC”. (B) Innovative Growth Factor Gene Therapy： Surv BioPharma is promoting research and development of gene therapy for Refractory Liver Diseases and Diabetes (Type 1) collaborated with Kagoshima University. First-generation candidate is going on pre-clinical stage.